Home About us Editorial board Ahead of print Browse Articles Search Submit article Instructions Subscribe Contacts Login 
  • Users Online: 299
  • Home
  • Print this page
  • Email this page

    Article Cited by others


Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence

Etemadifar Masoud, Salari Mehri, Mirmosayyeb Omid, Serati Mehdi, Nikkhah Roham, Askari Mozhde, Fayyazi Emad

Year : 2017| Volume: 22| Issue : 1 | Page no: 18-18

   This article has been cited by
1 Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models
Yan Wu,Lianmei Zhong,Jia Geng
Multiple Sclerosis and Related Disorders. 2019; 27: 412
[Pubmed]  [Google Scholar] [DOI]
2 Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study
V. Shaygannejad,E. Fayyazi,S. Badihian,O. Mirmosayyeb,N. Manouchehri,F. Ashtari,N. Asgari
Journal of Neurology. 2019;
[Pubmed]  [Google Scholar] [DOI]
3 B-cell Therapy for Multiple Sclerosis: Entering an era
Ariele L. Greenfield,Stephen L. Hauser
Annals of Neurology. 2018; 83(1): 13
[Pubmed]  [Google Scholar] [DOI]
4 Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab
K Shidahara,K Hayashi,K E Sada,S Hiramatsu,M Morishita,H Watanabe,Y Matsumoto,T Kawabata,J Wada
Lupus. 2018; 27(8): 1374
[Pubmed]  [Google Scholar] [DOI]
5 The link between morphology and complement in ocular disease
Camilla Mohlin,Kerstin Sandholm,Kristina N. Ekdahl,Bo Nilsson
Molecular Immunology. 2017;
[Pubmed]  [Google Scholar] [DOI]


Read this article